Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Northwestern University · Fox Chase Cancer Center · +5 more institutions
Abstract
PURPOSE: Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. PATIENTS AND METHODS: Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4…
Citation impact
- FWCI
- 86.95
- Percentile
- 100%
- References
- 24
Authors
8- BJBruce J. GiantonioCorresponding
Northwestern University, Fox Chase Cancer Center, Thomas Jefferson University, Mount Sinai Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, University of Pennsylvania
- PJPaul J. Catalano
Northwestern University, Fox Chase Cancer Center, Thomas Jefferson University, Mount Sinai Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, University of Pennsylvania
- NJNeal J. Meropol
Northwestern University, Fox Chase Cancer Center, Thomas Jefferson University, Mount Sinai Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, University of Pennsylvania
- PJPeter J. O’Dwyer
Northwestern University, Fox Chase Cancer Center, Thomas Jefferson University, Mount Sinai Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, University of Pennsylvania
- EPEdith P. Mitchell
Northwestern University, Fox Chase Cancer Center, Thomas Jefferson University, Mount Sinai Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida, University of Pennsylvania
Topics & keywords
- Bevacizumab
- Oxaliplatin
- Medicine
- Colorectal cancer
- Irinotecan
- Fluorouracil
- Internal medicine
- Chemotherapy
- Good health and well-being